• A
  • A
  • A
  • ABC
  • ABC
  • ABC
  • А
  • А
  • А
  • А
  • А
Regular version of the site

News

Discussion on the Regulation of the Pharmaceutical Industry: the IPNet group

On March 22, the Skolkovo Foundation together with the Institute for Law and Development organised a discussion on the problems in the field of intellectual property and competition in pharma. The event was another in a series of discussions conducted by the working group IPNet NTI, developing steps to change the regulatory environment for IP.

The participants were representatives of government agencies and business associations, experts, scientists, and innovative companies, and they discussed the initiative of the FAS on the commencement of the mechanism of compulsory licensing for medicines, instruments and procedures with the Federal service for intellectual property related to the issuance patents for medical drugs, as well as the possibility of the development of the pharmaceutical industry by removing barriers to entry of drugs into the market, expanding technology access for Russian producers and the bridging of regulatory chasms.

The discussions and presentations:

1) Antimonopoly regulation of the pharmaceutical market: the U.S. experience, Europe and the BRICS countries - lessons for Russia;
2) Compulsory licences - pros and cons for the development of the Russian pharmaceutical industry;
3) Reform of patent protection in the pharmaceutical industry - new challenges in healthcare development.

At the discussion:

Timothy Nizhegorodtsev, Head of the FAS Department for Regulation of Trade and the Social Sphere
Elena Gavrilova, Head of the FIPS Department of Chemistry, Biotechnology and Medicine presentation 
Alexey Ivanov, Director of the Department of Legal Policy and Public Development of the Skolkovo Foundation, Director of the HSE-Skolkovo Institute for Law and Development presentation 
Elena Voinikanis, Leading researcher of the HSE-Skolkovo Institute for Law and Development
Vadim Kukava, Executive Director, Association of Pharmaceutical Innovation